SCHEMBL15747232

SCHEMBL15747232

[N-]=[N+]=N[C@H]1C(O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O[C@H]1n1cnc2c(=O)[nH]c(N)nc21

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TGM2 P21980 1/20 0.65
▸ P2RY2 P41231 2/20 0.62
▸ P2RY4 P51582 2/20 0.62
▸ KRAS P01116 5/20 0.62
▸ FUT5 Q11128 1/20 0.61
▸ NT5E P21589 1/20 0.61
▸ P2RY6 Q15077 3/20 0.58
▸ P2RX3 P56373 3/20 0.56
▸ ENPP1 P22413 2/20 0.54
▸ P2RY1 P47900 2/20 0.54
▸ P2RX1 P51575 2/20 0.54
▸ P2RY11 Q96G91 1/20 0.54
▸ P2RX4 Q99571 1/20 0.54
▸ DCPS Q96C86 1/20 0.54
▸ POLB P06746 1/20 0.54
▸ P2RX2 Q9UBL9 1/20 0.53
▸ P2RY12 Q9H244 1/20 0.53
▸ TAS1R3 Q7RTX0 1/20 0.52
▸ TAS1R1 Q7RTX1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20850290 1.00 TGM2 (0.65) TGM2P2RY2P2RY4KRASFUT5
SCHEMBL18648317 1.00 TGM2 (0.65) TGM2P2RY2P2RY4KRASFUT5
SCHEMBL15794923 1.00 TGM2 (0.65) TGM2P2RY2P2RY4KRASFUT5
SCHEMBL29258529 0.93 NT5E (0.65) TGM2KRASFUT5NT5ETAS1R3
SCHEMBL15746474 0.91 P2RY2 (0.62) TGM2P2RY2P2RY4KRASFUT5
SCHEMBL16805285 0.91 P2RY2 (0.62) TGM2P2RY2P2RY4KRASFUT5
Guanosine Triphosphate SCHEMBL44408 0.89 TGM2 (0.81) TGM2P2RY2P2RY4KRASFUT5
Gtp SCHEMBL96708 0.89 TGM2 (0.81) TGM2P2RY2P2RY4KRASFUT5
SCHEMBL2593095 0.89 TGM2 (0.81) TGM2P2RY2P2RY4KRASFUT5
Gtp SCHEMBL18784960 0.89 TGM2 (0.81) TGM2P2RY2P2RY4KRASFUT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2017-06-22 — — US disclosed
US-20170136132-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2017-05-18 — — US disclosed
US-20170136131-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF Modema Therapeutics, Inc. (US) 2017-05-18 — — US disclosed
US-9597380-B2 Terminally modified RNA MODERNATX, INC. (US) 2017-03-21 — — US disclosed
US-20160354491-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-08 — — US disclosed
US-20160354492-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-08 — — US disclosed
US-20160354490-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-08 — — US disclosed
US-20160348099-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-01 — — US disclosed
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. 2016-10-20 — — US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 — — US disclosed
US-20160237108-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF ARES CAPITAL CORPORATION, AS AGENT 2016-08-18 — — US disclosed
US-20150307542-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNATX, INC. 2015-10-29 — — US disclosed
US-20150167017-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. 2015-06-18 — — US disclosed
US-20140147454-A1 TERMINALLY MODIFIED RNA MODERNA THERAPEUTICS, INC. (US) 2014-05-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160354492-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885P2RY2 2899/4885P2RY4 2901/4885
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 TGM2 2867/4885P2RY2 980/4885P2RY4 709/4885
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885P2RY2 2899/4885P2RY4 2901/4885
US-20160348099-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885P2RY2 2899/4885P2RY4 2901/4885
US-20170136132-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 TGM2 2234/4885P2RY2 2786/4885P2RY4 2985/4885
US-20160354490-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885P2RY2 2899/4885P2RY4 2901/4885
US-20160354491-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885P2RY2 2899/4885P2RY4 2901/4885
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 TGM2 2234/4885P2RY2 2786/4885P2RY4 2985/4885
US-20170136131-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 TGM2 2234/4885P2RY2 2786/4885P2RY4 2985/4885
US-20140147454-A1 TERMINALLY MODIFIED RNA RNGTT, NSUN3, RNMT TGM2 3781/4885P2RY2 4624/4885P2RY4 4574/4885
US-20150307542-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885P2RY2 2899/4885P2RY4 2901/4885
US-20160237108-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF NSUN3, POLRMT, TRDMT1 TGM2 2945/4885P2RY2 1975/4885P2RY4 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback